Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Liabilities and Shareholders Equity (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $259.1 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 31.5% to $259.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 27.57% year-over-year, with the annual reading at $259.1 million for FY2025, 31.5% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $259.1 million at Phathom Pharmaceuticals, up from $240.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $413.8 million in Q4 2023, with the low at $144.0 million in Q1 2023.
  • Average Liabilities and Shareholders Equity over 4 years is $267.1 million, with a median of $254.7 million recorded in 2025.
  • The sharpest move saw Liabilities and Shareholders Equity surged 151.1% in 2023, then plummeted 37.92% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $164.8 million in 2022, then soared by 151.1% to $413.8 million in 2023, then fell by 8.58% to $378.3 million in 2024, then crashed by 31.5% to $259.1 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $259.1 million, $240.3 million, and $250.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.